The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer
The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer
复制标题
DOI：
10.1038/bjc.2014.428
复制
发表时间：
2014-09-09
影响因子：
8.8
通讯作者：
Nam, R. K.
中科院分区：
文献类型：
--
作者：
Akbari, M. R.;Wallis, C. J. D.;Nam, R. K.
背景：BRCA2突变的男性面临前列腺癌的风险增加。这些癌症往往具有侵略性的性质，它还没有被证明，定期筛查BRCA2载体与提高survival.Methods：我们确定了4187名男性谁接受前列腺癌活检PSA升高或异常直肠指检在1998年和2010年之间。我们对BRCA2基因进行了全面的突变筛查，并对前列腺癌死亡的男性进行了随访，直至2012年12月。结果：无BRCA2突变的男性的12年前列腺癌特异性生存率为94.3%，有突变的男性为61.8结论：筛查发现的前列腺癌和BRCA2突变的男性的生存率比预期的要差得多。
Background: Men with a BRCA2 mutation face an increased risk of prostate cancer. These cancers tend to have an aggressive nature and it has not yet been demonstrated that regular screening of BRCA2 carriers is associated with improved survival.Methods: We identified 4187 men who underwent a prostate cancer biopsy for an elevated PSA or an abnormal digital rectal examination between 1998 and 2010. We screened the BRCA2 gene in its entirety for mutations and we followed the men for death from prostate cancer until December 2012.Results: The 12-year prostate cancer-specific survival rate was 94.3% for men without a BRCA2 mutation and was 61.8% for men with a mutation (P < 10(-4); log-rank test).Conclusions: The survival of men with screen-detected prostate cancer and a BRCA2 mutation is much poorer than expected.